An Open-Label, Parallel-Group Study Assessing the Pharmacokinetics, Saftey and Pharmacodynamics of Single Oral Dosing of Luseogliflozin in Patients with Hepatic Impairment (Mild to Moderate) and in Healthy Subjects

Trial Profile

An Open-Label, Parallel-Group Study Assessing the Pharmacokinetics, Saftey and Pharmacodynamics of Single Oral Dosing of Luseogliflozin in Patients with Hepatic Impairment (Mild to Moderate) and in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Luseogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 07 Aug 2017 Results published in the Clinical Pharmacology in Drug Development Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top